Matisse Pharmaceuticals receives FDA Fast Track Designation for isupartob sodium in sepsis

Matisse obtains FDA Fast Track Designation for isupartob sodium in sepsis. FDA's Fast Track is designed to get important new drugs to the patient earlier.